REVIEW ARTICLES  THE REPRODUCTIVE SYSTEM
Guest Editors: Freeman L. M., Bombardieri E. 

The Quarterly Journal of Nuclear Medicine 2002 June;46(2):131-7

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

The role of 111In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer

Freeman L. M., Krynyckyi B. R., Li, Y., Korupulu G., Saleemi K., Haseman M. K. *, Kahn D. **

Department of Nuclear Medicine Montefiore Medical Center and Albert Einstein College of Medicine Bronx, New York, USA * Sutter Community Hospital,Sacramento, CA, USA ** Jowa City Veterans Administration, Medical Center Jowa City, IA, USA

111In Cap­romab Pende­tide (Pros­taS­cintR) is a ­whole ­murine anti­body ­that is reac­tive ­with pros­tate spe­cific mem­brane ­antigen (­PSMA), a gly­co­pro­tein on the sur­face of ­normal and ­abnormal pros­tate epi­the­lium. It has ­proven to be of ­great ­value in ­assisting man­age­ment deci­sions in pros­tate ­cancer ­patients who ­initially ­present ­with ­high ­risk for met­a­static ­spread, or who ­develop a pic­ture of recur­rent dis­ease ­after sur­gery or radi­a­tion ­therapy. Pat­terns of met­a­static lym­phatic ­spread ­have cor­re­lated ­well ­with ­autopsy ­reports in the lit­er­a­ture. Unfor­tu­nately, ­other ­imaging ­study and/or his­to­logic con­fir­ma­tion of scin­ti­graphic find­ings has ­been dif­fi­cult to ­obtain. ­Prostascint’s ­role in pre­dicting dur­able com­plete ­response (DCR) in post­op­er­a­tive ­patients ­having sal­vage radio­therapy to ­their pros­tate ­fossa is ­very prom­ising. Fur­ther inves­ti­ga­tive ­work in ­larger ­patient pop­u­la­tions is ­needed to con­firm ­these ­early ­results.